Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
34ypQSnMagmGb35D